Background
==========

Among all countries, the incidence of end-stage renal disease (ESRD) (41.5 per 100,000) has been the highest in Taiwan since 2000 \[[@B1]-[@B4]\]. There were more than 2 million ESRD patients worldwide in 2010 requiring dialysis or transplantation \[[@B5]\]. It is well known that patients with diabetes mellitus and/or chronic kidney disease are at high risk of developing ESRD \[[@B3]-[@B7]\]. The prevalence of CKD has been shown to be higher in older adults in Taiwan \[[@B2]\], United States \[[@B6]\], Japan \[[@B7]\] and internationally \[[@B8],[@B9]\].

Dementia is a heterogeneous and multifactorial disorder, including vascular-type dementia and Alzheimer-type dementia \[[@B10]\]. The prevalence of dementia increases with age, from less than 1% in people aged 65 years to more than 25% in those aged 85 years or over \[[@B11],[@B12]\]. Dementia has been a hidden health issue in Taiwan in the elderly population. The prevalence of the disorder in the elderly in Taiwan increased continuously over past decades, from 4.1% in 1980, to 6.1% in 1990, to 8.6% in 2000 and to 10.2% in 2007 \[[@B13]\]. It is therefore important to identify protective and risk factors for dementia to prevent this disease at an early stage. CKD has been proposed as a major factor of developing ESRD. It is also an independent risk factor for cognitive impairment but with conflicting findings among studies. Dementia and CKD have been recognized as comorbidities with higher incidence rate among the elderly \[[@B10]\], Sasaki et al. further found the incidence rate of dementia in Osaki area patients with CKD was much higher than the general Japanese population (24.0% vs. 9.0%) \[[@B14]\].

Recent studies in the US have also shown that impaired kidney function is associated with the increased prevalence of cognitive impairment \[[@B15],[@B16]\]. Studies have identified age, hypertension and diabetes mellitus as independent factors in the association between kidney function and impaired cognition \[[@B14]-[@B17]\]. However, there were limited population based cohort studies on the association between CKD and the risk of dementia. To fill this research gap, we conducted this population based cohort study using claims data from the National Health Insurance (NHI) in Taiwan to explore issues of (i) the association between CKD and dementia in the aging population in Taiwan, (ii) the role of other comorbidities in the risk of dementia, (iii) the relationship between medications and the risk of dementia.

Methods and materials
=====================

Data sources
------------

The National Health Insurance (NHI) of Taiwan is a universal health insurance program reformed in 1995, offers the coverage to 99% of the nation's population of 23 million, and approximately 97% of hospitals and clinics have contracted with the NHI \[[@B18]\]. For research and administrative purposes, the National Health Research Institute, Taiwan, has used the claims data to establish various sets of database for public uses. This study used a longitudinal dataset including one-million insured people randomly selected from the whole population covered by the NHI. This dataset contains information on all medical services, such as ambulatory care claims, inpatient claims and prescription drugs and registry beneficiaries \[[@B18]-[@B20]\]. The privacy of all patients was protected by the encryption of personal identification. Using the unique scrambled personal identifications, we were able to link these to obtain medical histories and demographic variables. This study was exempted from full institutional review.

Study subjects
--------------

In this study, we identified study subjects from 2000 to 2006 with newly diagnosed chronic kidney disease (CKD) as CKD cohort and those without any CKD diagnosis as non-CKD cohort. Subjects in the CKD cohort were identified using International Classification of Diseases 9^th^ Revision, Clinical Modification \[ICD-9-CM\], including 250.4(diabetes with renal manifestations), 274.1(gouty nephropathy), 403(hypertensive chronic kidney disease)- 404(hypertensive heart and chronic kidney disease), 440.1(disease of renal artery), 442.1(disease of renal artery), 447.3(hyperplasia of renal artery), 581(nephritic syndrome)-583(nephritis and nephropathy), 585(chronic renal failure)-588(disorders resulting from impaired renal function). Inpatients with at least one CKD diagnosis or outpatients with twice CKD service claims were included in the CKD cohort. Patients with codes of 283.1(hemolytic uremic syndrome), 572.4 (hepatorenal syndrome), 642.1(Hypertension secondary to renal disease, complicating pregnancy, childbirth, and the puerperium) and 646.2(Unspecified renal disease in pregnancy, without mention of hypertension) were excluded. Patients who had diagnoses of ESRD, renal transplantation therapy or dialysis therapy were also excluded. The first date of diagnosed CKD was the index date for the follow-up time measure. Subjects with dementia (ICD-9-CM 290.0, 290.1, 290.2, 290.3, 290.4, 294.1 and 331.0) prior to the index date or with missing information on gender or age were also excluded from this study.

For each CKD patient, two non-CKD subjects were randomly selected frequency matching with gender, age (every 5 years), index-year and index-month. The exclusion criteria used to select CKD cohort were used to select non-CKD cohort. We also avoid selecting subjects developing CKD in the non-CKD cohort, during the follow-up period. The follow-up time in person-years was calculated for each study subject until the occurrence of dementia, the end of 2009 or censored because of deaths or withdrawal from the insurance program. Other considered comorbidities at the baseline were hypertension (ICD-9-CM 401--405, A-code A260 and A269), diabetes mellitus (ICD-9-CM 250 and A-code A181), ischemic heart disease (ICD-9-CM 410--414, A-code A270 and A279), hyperlipidemia (ICD-9-CM 272.0, 272.1, 272.2, 272.3 and 272.4), tobacco use disorder (ICD-9-CM 305.1), alcoholism (ICD-9-CM 291, 291.2, 291.9, 303.9, 334.4, 980.0, V11.3, V79.1 and V61.41), morbid obesity (ICD-9-CM 278.0, 278.00, 278.01, 649.1, 783.1 and V77.8), atrial fibrillation (ICD-9-CM ), Parkinson\'s disease (ICD-9-CM 332 and A-code A221), cerebrovascular disease (ICD-9-CM 430--438, A-code A290-A294 and A299), major depressive disorder (ICD-9-CM 296.2 and 296.3), and elevated C-reactive protein screen (ICD-9-CM 790.95). The analysis of medication drugs related to dementia was performed for the use of benzodiazepine, aspirin, other NSAIDs and COX2.

Statistical analysis
--------------------

Data analysis first compared the demographic status and comorbidites between CKD and non-CKD cohorts. The Chi-square test was used to compare the difference in gender, age and baseline comorbidities between the CKD and non-CKD cohorts. Student's *t*-test was used to compare the difference in mean age. Incidence rates of dementia for both cohorts, and the CKD cohort to non-CKD cohort incidence rate ratio (IRR) and 95% confidence interval (CI) were estimated by gender, age and follow-up time (\< 2 and ≥ 2 years). We estimated incidence rates of dementia by comorbidity and medication, and used Cox proportional hazards regression model to estimate the specific hazard ratio (HR) and 95% confidence intervals of dementia for the CKD cohort compared to the non-CKD cohort. The Cox model was also used to estimate age, sex, comorbidity and medication specific crude HRs of dementia and the multivariate adjusted HRs. All analyses were performed using SAS software version 9.1 (SAS Institute Inc., Cary, NC), and the statistical significance level was set at two-sided *p* \< 0.05.

Results
=======

There were more men than women in both cohorts (54.2% vs. 45.8%), with the mean age slightly greater in the CKD cohort than the non-CKD cohort (Table [1](#T1){ref-type="table"}). Approximately 15% of subjects were young in 20--39 years of age. Subjects with CKD had a higher prevalence of all baseline comorbidities and medications (*p* \< 0.0001). Table [2](#T2){ref-type="table"} shows that the incidence of dementia was higher in the CKD cohort than in the non-CKD cohort (9.30 vs. 5.55 per 1,000 person-years), with an IRR of 1.68 (95% CI 1.58-1.78). The incidence was slightly higher in women than in men, increased with age. But the age-specific relative risk was the highest for the youngest subcohort with an IRR of 16.0 (95% CI 2.00-128.0), and the lowest for the elderly with the IRR of 1.75 (95% CI 1.64-1.86). The IRR declined slightly after a 2-year follow-up.

###### 

**Baseline characteristics between CKDcohort and non-CKD cohort**

  -------------------------------------------------------------------------------------------
                                 **non-CKD**\      **CKD**\                      
                                 **N = 74098**   **N = 37049**                   
  ----------------------------- --------------- --------------- ------- -------- ------------
  Sex                                                                                1.00

  Women                              33948           45.8        16974    45.8         

  Men                                40150           54.2        20075    54.2         

  Age group (years)                                                                  1.00

  20--39                             10710           14.5        5355     14.5         

  40--64                             34742           46.9        17371    46.9         

  ≥65                                28646           38.7        14323    38.7         

  Mean (SD) (years)                  57.5           (15.8)       58.3    (16.1)    \<0.0001

  Co-morbidities                                                                       

  Hypertension                       23702           32.0        21731    58.7    \<0.0001\*

  Diabetes mellitus                  6367            8.59        11517    31.1    \<0.0001\*

  Ischemic heart disease             12896           17.4        12056    32.5    \<0.0001\*

  Hyperlipidemia                     7350            9.92        9762     26.4    \<0.0001\*

  Tobacco use disorder                138            0.19         135     0.36    \<0.0001\*

  Alcoholism                          294            0.40         335     0.90    \<0.0001\*

  Obesity                             398            0.54         401     1.08    \<0.0001\*

  Atrial fibrillation                 638            0.86         740     2.00    \<0.0001\*

  Parkinson\'s disease                790            1.07         680     1.84    \<0.0001\*

  Cerebrovascular disease            8701            11.7        7876     21.3    \<0.0001\*

  Major depressive disorder           852            1.15         652     1.76    \<0.0001\*

  Elevated C-reactive protein         \--                         \--                \--

  Medication                                                                           

  Use of benzodiazepine              37902           51.2        25284    68.2    \<0.0001\*

  Use of aspirin                     6992            9.44        5822     15.7    \<0.0001\*

  Use of other NSAIDs                63174           85.3        34698    93.7    \<0.0001\*

  Use of COX2                        14584           19.7        10901    29.4    \<0.0001\*
  -------------------------------------------------------------------------------------------

^\*^Chi-square test comparing patients with and without CKD.

###### 

**Incidence of dementia estimatedby sex, age, andfollow-up years for CKDand non-CKD cohorts**

                          **Non-CKD**   **CKD**                                                        
  ---------------------- ------------- --------- -------- ------ ------- ------ -------- ------ ------ -------------
  All                        74098       2621     472301   5.55   37049   2013   216301   9.30   1.68   (1.58-1.78)
  Sex                                                                                                  
  Women                      33948       1293     222306   5.82   16974   969    102586   9.45   1.62   (1.49-1.77)
  Men                        40150       1328     249995   5.31   20075   1044   113795   9.17   1.73   (1.59-1.87)
  Age, years                                                                                           
  20--39                     10710         1      72841    0.01   5355     8     36456    0.22   16.0   (2.00-128)
  40--64                     34742        262     234351   1.12   17371   298    111467   2.67   2.39   (2.03-2.82)
  ≥65                        28646       2358     165109   14.3   14323   1707   68458    24.9   1.75   (1.64-1.86)
  Follow-up time, year                                                                                 
  \< 2                       74098        696     144691   4.81   37049   651    68898    9.45   1.96   (1.77-2.18)
  ≥ 2                        70600       1925     327610   5.88   32917   1362   147483   9.23   1.55   (1.43-1.67)

^†^ Incidence rate: per 1,000 person-years.

IRR (Incidence rate ratio): CKD vs. non-CKD (95% CI).

Table [3](#T3){ref-type="table"} presents the comorbidity-specific incidence rates of dementia in both cohorts and the CKD cohort to non-CKD cohort hazard ratios after controlling for age, sex, and medications. Most of comorbidities are associated with increased dementia incidence, the highest for CKD patients with the comorbidity of Parkinson\'s disease (50.9 per 1,000 person-years), followed by those with atrial fibrillation (29.9 per 1,000 person-years), cerebralvascular disease (25.1 per1,000 person-years), etc. These comorbidites were also associated with increased dementia incidence for non-CKD subjects.

###### 

**Incidence of dementia estimatedby comorbidity for CKDand non-CKD cohorts**

                               **Non-CKD**   **CKD**                        
  --------------------------- ------------- --------- ------ ------- ------ -------------
  Hypertension                                                              
  No                               995        3.01     337    3.48    1.64   (1.45-1.86)
  Yes                             1626        11.5     1676   14.02   1.48   (1.38-1.58)
  Diabetes mellitus                                                         
  No                              2212        5.08     1203   7.83    1.52   (1.42-1.64)
  Yes                              409        11.2     810    12.9    1.42   (1.26-1.60)
  Ischemic heart disease                                                    
  No                              1680        4.23     921    6.05    1.63   (1.50-1.76)
  Yes                              941        12.5     1092   17.0    1.52   (1.39-1.65)
  Hyperlipidemia                                                            
  No                              2286        5.33     1491   9.36    1.65   (1.54-1.78)
  Yes                              335        7.78     522    9.14    1.43   (1.25-1.64)
  Tobacco use disorder                                                      
  No                              2620        5.55     2007   9.30    1.60   (1.51-1.70)
  Yes                               1         1.81      6     11.1    6.73   (0.81-56.1)
  Alcoholism                                                                
  No                              2608        5.54     1992   9.27    1.60   (1.50-1.69)
  Yes                              13         8.72      21    14.8    2.88   (1.41-5.91)
  Obesity                                                                   
  No                              2614        5.56     2001   9.34    1.60   (1.51-1.70)
  Yes                               7         3.13      12    5.32    2.81   (1.04-7.58)
  Atrial fibrillation                                                       
  No                              2562        5.46     1929   9.03    1.59   (1.50-1.69)
  Yes                              59         19.2      84    29.9    1.67   (1.19-2.33)
  Parkinson\'s disease                                                      
  No                              2482        5.30     1876   8.78    1.61   (1.51-1.71)
  Yes                              139        38.0     137    50.9    1.30   (1.02-1.65)
  Cerebrovascular disease                                                   
  No                              1701        4.01     1048   5.89    1.59   (1.47-1.72)
  Yea                              920        19.2     965    25.1    1.41   (1.28-1.54)
  Major depressive disorder                                                 
  No                              2546        5.44     1949   9.15    1.61   (1.51-1.71)
  Yes                              75         16.5      64    18.8    1.44   (1.03-2.03)

^†^ Incidence rate: per 1,000 person-years.

HR: CKD vs. non-CKD (95% CI), adjsued for age, sex, use of benzodiazepine, aspirin, other NSAIDs and COX2.

The CKD cohort had a higher risk of dementia than the non-CKD cohort (adjusted HR 1.41, 95% CI 1.32-1.50) in the multivariate Cox model (Table [4](#T4){ref-type="table"}). There was no significant different in the dementia risk between men and women. The adjusted hazard of dementia was much greater for the elderly (HR 133.0, 95% CI 68.9-256), compared with those in 20--39 years of age. CKD patients with the comorbidity of Parkinson\'s disease had a crude HR of 6.92 (95% CI 6.13-7.82), compared with the non-CKD cohort. The risk remained significant (HR = 1.80, 95% CI 1.59-2.04) in the multivariate analysis. However, the HR in the multivariable model was the highest for patients with alcoholism (HR = 3.05, 95% CI 2.17-4.28). Some other comorbidities could also predict the elevated hazard of dementia for patients with CKD, except for ischemic heart disease, hyperlipidemia, obesity, atrial fibrillation and the use of aspirin and other NSAIDs. The crude HR associated with hyperlipidemia was significant, but became protective in the multivariable analysis. Taking benzodiazepines were also associated with the dementia risk.

###### 

**Cox model measured hazardratios and 95% confidenceintervals of dementia associatedwith CKD and covariates**

                               **Crude**   **Adjusted**^**†**^         
  --------------------------- ----------- --------------------- ------ -------------
  Sex                                                                  
  Women                          1.00                            1.00         
  Men                            0.94          (0.89-1.00)       0.97   (0.92-1.03)
  Age, years                                                           
  20--39                         1.00                            1.00         
  40--64                         19.7          (10.2-38.0)       16.1   (8.35-31.2)
  ≥65                             216          (112.-414)        133    (68.9-256)
  CKD                                                                  
  No                             1.00                            1.00         
  Yes                            1.68          (1.58-1.78)       1.41   (1.32-1.50)
  Hypertension                                                         
  No                             1.00                            1.00         
  Yes                            4.10          (3.85-4.37)       1.17   (1.09-1.26)
  Diabetes mellitus                                                    
  No                             1.00                            1.00         
  Yes                            2.14          (2.00-2.28)       1.25   (1.17-1.34)
  Ischemic heart disease                                               
  No                             1.00                            1.00         
  Yes                            3.11          (2.94-3.30)       1.00   (0.93-1.06)
  Hyperlipidemia                                                       
  No                             1.00                            1.00         
  Yes                            1.35          (1.25-1.45)       0.89   (0.83-0.97)
  Tobacco use disorder                                                 
  No                             1.00                            1.00         
  Yes                            1.00          (0.48-2.09)       \--          
  Alcoholism                                                           
  No                             1.00                            1.00         
  Yes                            1.78          (1.27-2.49)       3.05   (2.17-4.28)
  Obesity                                                              
  No                             1.00                            1.00         
  Yes                            0.64          (0.41-1.00)       0.93   (0.59-1.46)
  Atrial fibrillation                                                  
  No                             1.00                            1.00         
  Yes                            3.77          (3.19-4.45)       1.17   (0.99-1.39)
  Parkinson\'s disease                                                 
  No                             1.00                            1.00         
  Yes                            6.92          (6.13-7.82)       1.80   (1.59-2.04)
  Cerebrovascular disease                                              
  No                             1.00                            1.00         
  Yes                            4.85          (4.57-5.14)       1.72   (1.61-1.84)
  Major depressive disorder                                            
  No                             1.00                            1.00         
  Yes                            2.68          (2.26-3.17)       1.95   (1.64-2.31)
  Use of benzodiazepine                                                
  No                             1.00                            1.00         
  Yes                            2.54          (2.37-2.71)       1.23   (1.14-1.32)
  Use of aspirin                                                       
  No                             1.00                            1.00         
  Yes                            1.85          (1.71-2.00)       1.02   (0.95-1.11)
  Use of other NSAIDs                                                  
  No                             1.00                            1.00         
  Yes                            1.54          (1.39-1.70)       1.01   (0.91-1.12)
  Use of COX2                                                          
  No                             1.00                            1.00         
  Yes                            2.45          (2.31-2.60)       1.09   (1.02-1.16)

^†^ Adjusted for sex, age, CKD, hypertension, diabetes mellitus, ischemic heart disease, hyperlipidemia, alcoholism, obesity, atrial fibrillation, Parkinson\'s disease, cerebrovascular disease, major depressive disorder, use of benzodiazepine, aspirin, other NSAIDs and COX2.

Discussion
==========

This study revealed that the risk of dementia in the CKD cohort was higher than that in the non-CKD cohort yield a HR of 1.04 after controlling for demographic variables and medical conditions. This result is comparable with the findings in previous studies. Nickolas et al. found that the mild cognitive impairment in older adults with CKD is also a potentially modifiable risk factor for dementia \[[@B21]\]. Another survey revealed that moderate to severe CKD in stroke-free subjects was associated with white matter hyperintensity, which is resulted from inflammation and endothelial dysfunction and is a risk for dementia \[[@B22],[@B23]\]. In addition, the present study supports previous findings of the relationship between impaired kidney function and cognitive decline \[[@B16],[@B17],[@B22],[@B24]-[@B26]\]. Kahtri et al found that patients with kidney disease even with mild CKD 訂 e at an elevated risk of cognitive impairment \[[@B24]\].

It is important to note that a large proportion of CKD patients were young, aged 20-39 years, accounting for approximately 15% in the cohort. The young CKD patients to the young non- CKD patients IRR of dementia was near 9-fold greater than that for the elderly, reflecting CKD has a strong impact for young people. The corresponding IRR for 40-64 years was 13.6-fold greater than the elderly. Our data also showed that the risk of dementia declined with longer follow-up time, indicating dementia may develop in earlier period of CKD. Prevention care should be started earlier period including younger CKD patients.

This study also found several comorbidities and medications could predict dementia. The associations between blood pressure, diabetes and dementia and cognitive impairment have received much attention in studies, but the results are somewhat in conflict \[[@B25]-[@B32]\]. High blood pressure increases the risk of dementia in the elderly \[[@B26],[@B30]\]. Xu et al. found that the risk of dementia was especially high for patients with diabetes mellitus and severe systolic hypertension \[[@B30]\]. Our results echo most of previous findings that hypertension and diabetes are independent predictors of dementia \[[@B32]\].

An earlier study has found that very old women with myocardial infarction are 5-time more likely prone to dementia than those without the disease \[[@B33]\]. The cross-sectional analysis from the Rotterdam study showed that the prevalence of dementia was increased with the degree of peripheral arterial atherosclerotic disease. The odds ratio for cognitive decline in those with severe atherosclerosis was 3:0 \[[@B34]\]. Our study showed that CKD patients with ischemic heart disease were 2.8-fold (17.0 vs. 6.05 per 1000 person-years) more likely than CKD patients without the comorbidity for the risk of dementia. This association became insignificant in the multivariate analysis.

Among comorbidities, alcoholism has the strongest association with dementia in this study. Breteler found a significant relationship between alcohol intake and the risk of vascular disease \[[@B35]\]. Those with moderate alcohol intake may not at an increased risk of dementia \[[@B36]-[@B38]\]. The congnitive impairment due to alcohol addition has been 臼 ported as alcohol dementia \[[@B29],[@B39]\]. Alcoholism was less prevalent in our study population,but it is an important risk factor of dementia.

In addition to alcoholism, hypertension and diabetes, we also found that cerebrovascular disease, Parkinson\'s disease and major depressive disorder were significant comorbidities associated with dementia. Studies have reported cerebrovascular disease as a major contributor to later-life dementia \[[@B31],[@B40]-[@B44]\]. Our findings reiterate previous pathological investigations. The later epidemiological studies may have raised the possibility that cerebrovascular disease and dementia are two disorders causally related \[[@B42]\]. Parkinson\'s disease and the major depressive disorder are relatively less important than cerebrovascular disease in the association with the dementia risk \[[@B45]-[@B47]\].

Hyperlipidemia had a significant risk of dementia in the univariate model but it became a protective effect after being adjusted. In subjects without hyperlipidemia, the incidence of dementia in CKD patients is higher than non-CKD patients (9.36 vs. 5.33 per 1,000 person-years). However ,the incidence in CKD patients with hyperlipidemia declined to 9.14 per 1,000 person-years. The association between hyperlipidemia and dementia is not clear. The colinearity of hypertension and hyperlipidemia may explain the phenomenon.

The significant relation between dementia and medications of benzodiazepines agents and aspirin is another important finding in this study. Previous studies have reported that the long-term use of benzodiazepines agents is responsible for moderate-to-large weighted risk of dementia \[[@B48]-[@B52]\]. The aspirin use might pose an increased risk of intracerebral hemorrhages \[[@B53]\]. It is not clear whether this is the mechanism increases the risk of dementia.

Limitations
-----------

The insurance claims data provided no measures of serum creatinine and microalbuminuria, and we were unable to evaluate the dementia risk based on kidney function. CKD patients at an earlier stage might not be included in the study. This may, therefore, have resulted in estimating the risk for patients with more severe condition of CKD. Second, as diagnosis of CKD and dementia requires long-term observation for clinical manifestation, the seven-year or less observation period in this study may be insufficient to estimate the dementia risk with the full course of natural history. The associated risk measures may be thus underestimated.

Third, this study included conmorbidity information at the baseline, prior to the date of establishing the study cohorts. Comorbidities developed during the follow-up period may vary and the estimation of dementia risk may vary.

Conclusions
===========

This study evaluated the risk of dementia in associations with CKD and several medical conditions and medications for the Asian population, using representative population-based data. We have demonstrated that patients with CKD are at a significantly higher risk of dementia than those without CKD. Other comorbidity may also interact with CKD and increase further the risk of dementia. CKD is a much more prevalent disorder in the current study population than populations of many other countries. Studies are needed for patients with CKD not only for the prevention of developing end stage renal disease, but also for preventing the progression of dementia. The identification of comorbidities and medications may yield important prevention opportunity for reducing dementia development. Our data suggest that intervention should be applied to young patients as well.
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